Navigation Links
Major breakthrough in the treatment of cancers and infectious diseases

Montreal researchers identify new anti-cancer, anti-infection response control mechanism

Dr. André Veillette, a researcher at the Institut de recherches cliniques de Montréal (IRCM), and his team will publish in the upcoming issue of the prestigious journal Nature Immunology of Nature Publishing Group, a discovery that could significantly advance the treatment of cancers and infectious diseases. Current treatments frequently achieve only limited results with these types of diseases, which affect hundreds of thousands of Canadians.

Dr. Veillette's team identified one of the basic mechanisms controlling NK ("natural killer") cell activity. Produced by the immune system, NK cells are responsible for recognizing and killing cancer cells and cells infected by viruses such as the viruses causing hepatitis and herpes. NK cell deficiency is associated with a higher frequency of cancers and serious infections. Dr. Veillette's breakthrough demonstrates that a molecule known as EAT-2, present in NK cells, suppresses its killer function. Inhibiting EAT-2 with medications could boost NK cell activity, helping to combat cancers and infections.

This publication constitutes a significant milestone for Dr. Veillette, an internationally renowned expert in the identification of the molecular mechanisms controlling the immune system. The article, which is slated for publication online on August 28 in Nature Immunology, gives genetic evidence for the inhibiting role of EAT-2 in NK cells. It is the product of over five years of intensive research by Dr. Veillette's team.

More specifically, by studying mice in which the EAT-2 protein is eliminated through genetic manipulations, Dr. Veillette's team has established that suppressing EAT-2 results in the production of NK cells that are much more effective at killing cancer cells. Inhibiting the function of EAT-2 with medications could therefore stimulate the killer function of NK cells, and increase their ca pacity to destroy cancer and virus-infected cells. These medications could be used in combination with chemotherapy and radiotherapy to improve the effectiveness of anti-cancer treatments. Teams around the world have been trying without success for many years to develop methods to increase NK cell activity. In this light, the discovery of Dr. Veillette's team opens new avenues for the treatment of cancers and communicable diseases.


'"/>

Source:Institut de recherches cliniques de Montreal


Related biology news :

1. Major new UNC-based drinking water study suggests pregnancy fears may be overstated
2. Major advance made on DNA structure
3. Major WHO study concludes calcium supplements can reduce complications during pregnancy
4. Major obesity gene is lost in the shuffle
5. Major initiative proposed to address amphibian crisis
6. Major cancer study aims to identify protein markers for early-stage disease
7. Major link in brain-obesity puzzle found
8. Major gene study uncovers secrets of leukemia
9. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
10. MUHC researchers make cancer target breakthrough
11. Researchers report breakthrough against world’s deadliest viruses
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps ... and North America this May on the following dates: , ?    London, ... Taylor, Chairman of the Learning and Performance Institute will be the opening ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... supplier of Common Lisp (CL) development tools, and market leader for Semantic ... key performance enhancements now available within the most effective system for developing and ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
Breaking Biology Technology: